This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Numerous investigators make tremendous and respectable efforts so that well-designed and -executed prospective, double-blind, randomized, controlled trials can determine definitively whether therapies of interest are indeed safe and effective. In this issue of Neurology®, Schoenen et al.1 report the results of such a trial conducted at 5 tertiary headache centers in Belgium. They determined whether migraine attacks can be prevented by trigeminal neurostimulation with a supraorbital transcutaneous stimulator: Cefaly. This stimulation device is fashionably designed and its frame resembles a lightweight tiara or sporty sunglasses.
Footnotes
See page 697
- © 2013 American Academy of Neurology
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.